bearish
Shanghai Henlius (复宏汉霖) IPO: Take-Aways from Peer PD-1 Sales in China
547 Views18 Sep 2019 15:37
We have gathered the sales data for PD-1 products from four players in China for the first half of 2019. As its anti-PD-1 monoclonal antibody,...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- ECM Weekly (28 Sep 2019) - Metro Pacific Hospitals, Topsports, ESR Cayman, JS Global28 Sep 2019
- Henlius (复宏汉霖) Post-IPO Trading: Weak Demands Ahead of Debut, Downside Remains25 Sep 2019
- ECM Weekly (21 Sep 2019) - Lendlease Global REIT, Budweiser APAC, Shanghai Henlius Bio21 Sep 2019
- Shanghai Henlius (复宏汉霖) IPO: Newsflow on HLX10 Clinical Trial and ASEAN Commercialization13 Sep 2019
- Shanghai Henlius (复宏汉霖) IPO: Thoughts on Price Range, Cornerstone, Valuation Trap11 Sep 2019
x